Compare RGP & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | EQ |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.5M | 140.1M |
| IPO Year | 2000 | 2018 |
| Metric | RGP | EQ |
|---|---|---|
| Price | $4.10 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | 261.1K | ★ 385.8K |
| Earning Date | 04-08-2026 | 05-25-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | ★ 79.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,006,000.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $0.76 |
| 52 Week High | $5.55 | $3.54 |
| Indicator | RGP | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 40.88 |
| Support Level | $4.17 | $1.97 |
| Resistance Level | $4.24 | $2.58 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 51.75 | 5.88 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.